Sign In
Buy AGRX
$1.51
+0 (+0%)
At Close: Nov 25, 2024
Agile Therapeutics Inc. Announces Completion of Acquisition by Insud Pharma, S.L.
05:05pm, Monday, 26'th Aug 2024
Agile Therapeutics has combined with Insud Pharma's US Subsidiary, Exeltis USA, Inc., expanding an already significant women's health/contraceptive portfolio
Dublin, Aug. 07, 2024 (GLOBE NEWSWIRE) -- The "Agile Leadership for Pharma and Biopharma Professionals in a hybrid world Training Course" conference has been added to ResearchAndMarkets.com's offering
STOCKHOLDER INVESTIGATION: The M&A Class Action Firm Investigates Merger of Agile Therapeutics, Inc. - AGRX
12:32pm, Wednesday, 03'rd Jul 2024
NEW YORK , July 3, 2024 /PRNewswire/ -- Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securiti
AGRX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Agile Therapeutics, Inc. Is Fair to Shareholders
10:26am, Wednesday, 26'th Jun 2024
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Agile Therapeutics, Inc. (OTCQB: AGRX) to Insud Pharma, S.L. for $1.52 per share in cash
Agile Therapeutics Inc. Announces Definitive Merger Agreement with Insud Pharma, S.L.
07:45am, Wednesday, 26'th Jun 2024
Agile Therapeutics will combine with Insud Pharma's US Subsidiary, Exeltis, expanding an already significant Women's Health/contraceptive portfolio
Agile Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
04:10pm, Wednesday, 15'th May 2024
First Quarter Net Revenue Increased 58% and Factory Sales Increased 3% from Fourth Quarter 2023 Twirla First Quarter 2024 Demand Rebounded 18% from Fourth Quarter 2023 PRINCETON, N.J., May 15, 2024 (G
Agile Therapeutics, Inc. (AGRX) Q4 2023 Earnings Call Transcript
10:46am, Thursday, 28'th Mar 2024
Agile Therapeutics, Inc. (AGRX) Q4 2023 Earnings Call Transcript
Agile Therapeutics Reports Fourth Quarter & Full Year 2023 Financial Results and Provides Corporate Update
08:05am, Thursday, 28'th Mar 2024
Full Year 2023 Net Revenue Increased 80% from 2022 While OPEX Decreased 33% Twirla Demand and Factory Sales Up 121% and 114% Respectively in 2023 vs 2022 Company Completes Pay-Off of Debt Facility in
Agile Therapeutics Announces Delisting from Nasdaq
04:30pm, Monday, 25'th Mar 2024
PRINCETON, N.J., March 25, 2024 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX) (“Agile Therapeutics” or the “Company”), a women's healthcare company, today announced that the Comp
PRINCETON, N.J., March 21, 2024 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced it will report fourth quarter and full year 2023 financial r
Agile Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on Friday, March 22, 2024
08:15am, Wednesday, 20'th Mar 2024
PRINCETON, N.J., March 20, 2024 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced it will report fourth quarter and full year 2023 financial r
Agile Therapeutics Completes Pay-off of Debt and Remains Focused on Business Plan Execution
07:31am, Wednesday, 13'th Mar 2024
Elimination of Remaining Debt to Perceptive Advisors Leaves the Company's Balance Sheet Debt Free Elimination of Remaining Debt to Perceptive Advisors Leaves the Company's Balance Sheet Debt Free
Agile Therapeutics Announces Exercise of Warrants for $4.8 Million Gross Proceeds
09:01am, Thursday, 22'nd Feb 2024
PRINCETON, N.J., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX) (“Agile Therapeutics” or the “Company”), a women's healthcare company, today announced the entry into
Why Is Agile Therapeutics (AGRX) Stock Up 87% Today?
07:57am, Thursday, 22'nd Feb 2024
Agile Therapeutics (NASDAQ: AGRX ) stock is rocketing higher on Thursday alongside heavy trading of the women's healthcare company's shares. During pre-market trading this morning, more than 7.5 mill
Company Granted Extension by Nasdaq Hearings Panel to Regain Compliance with the Stockholders' Equity Continued Listing Requirement Until March 25, 2024
